NCT06072781 2026-03-17
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
Clinical Trials
67 trialsNCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06930859 2026-03-16
ELEGANCE
Novartis
Recruiting
NCT07085767 2026-03-16
OPERA-02
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT04886531 2026-03-12
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT06790693 2026-03-06
INAVO123
Hoffmann-La Roche
Phase 3 Recruiting
NCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT04852887 2026-03-03
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT05768139 2026-03-02
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT05827081 2026-03-02
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06760637 2026-03-02
FourLight-3
Pfizer
Phase 3 Recruiting
NCT05467891 2026-02-27
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT06507618 2026-02-24
POWER II
University of Virginia
Phase 3 Recruiting
NCT07288359 2026-02-23
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT06905301 2026-02-20
IMPULSE
Novartis
Recruiting
NCT06998407 2026-02-20
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06348134 2026-02-17
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Phase 2 Recruiting
NCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06143631 2026-02-03
PLUM
University of California, San Francisco
Phase 4 Recruiting
NCT06394804 2026-02-03
CHAMELEON
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07019363 2026-01-21
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University
Phase 3 Recruiting
NCT05286437 2025-12-30
LaPemERLA
National Cancer Centre, Singapore
Phase 2 Recruiting
NCT06974929 2025-12-30
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT05035836 2025-12-22
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07285382 2025-12-16
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT04563507 2025-12-15
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06139107 2025-11-14
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
Phase 1 Recruiting
NCT04569747 2025-11-13
ADEPT
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04111978 2025-09-29
MATAO
Swiss GO Trial Group
Phase 3 Recruiting
NCT04486352 2025-09-04
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT06041204 2025-09-03
Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism
Al-Azhar University
Phase NA Recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT05512364 2025-08-19
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT04606446 2025-08-13
KAT6
Pfizer
Phase 1 Recruiting
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05181033 2025-07-25
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
National University Hospital, Singapore
Phase 2 Recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT06555068 2025-06-22
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT03675893 2025-06-15
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04614194 2025-06-02
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT05464810 2025-05-23
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Emory University
Phase EARLY_PHASE1 Recruiting